GDF15 mimetics
Targeting the cachexia / nausea / appetite pathway from a different angle than GLP-1.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
GDF15 is the body's own appetite-suppression and stress-response cytokine. Engineered mimetics could provide GLP-1-like effects through an entirely different receptor system.
- Class
- GDF15 (cytokine) and engineered analogs
- Sponsor
- Multiple programs (NGM Bio, Lilly, others)
- Stage
- Preclinical / early Phase 1
- Lead use case
- Obesity, cachexia, metabolic disease
What it is
Growth differentiation factor 15 (GDF15) is a stress-response cytokine produced by tissues under various stresses (hypoxia, inflammation, mitochondrial dysfunction, pregnancy). It binds GFRAL receptors expressed almost exclusively in the area postrema and nucleus of the solitary tract — brainstem regions involved in nausea and appetite regulation.
Current research status
Several engineered GDF15 analogs and mimetics are in preclinical or early Phase 1 development. Native GDF15 levels are elevated in cancer cachexia, pregnancy (where they contribute to nausea), and metformin therapy (which is part of metformin's modest weight-loss effect).
Mechanistic rationale
GFRAL is the orphan-receptor co-receptor for GDF15, complexed with RET. Activation produces appetite suppression and (at higher levels) nausea and emesis. The receptor's restriction to specific brainstem nuclei makes GDF15 unusually targeted in its appetite-regulation effects compared to broader pathway interventions.
Available evidence
Genetic evidence — GDF15 polymorphisms are associated with hyperemesis gravidarum and other appetite/nausea-related phenotypes.[1]
Preclinical mimetics — Engineered GDF15 analogs have shown weight-loss effects in rodent and primate models, with appetite suppression as the primary mechanism.
Early human work — Phase 1 studies of GDF15 analogs are characterizing pharmacokinetics and dose-response in healthy volunteers and in obesity contexts.
Why it's interesting
The GFRAL pathway is mechanistically distinct from GLP-1, GIP, glucagon, amylin, and PYY axes. A GDF15 mimetic could provide an additional therapeutic axis for obesity, particularly in patients who don't respond to or tolerate the incretin class. The receptor's tissue restriction (predominantly brainstem) suggests potentially cleaner appetite-specific effects.
Limitations & risks
The therapeutic window is narrow — appetite suppression and nausea are produced by overlapping receptor activation, and engineering compounds that suppress appetite without producing intolerable nausea is the central challenge. Native GDF15 elevation contributes substantially to chemotherapy- and pregnancy-related nausea, which is why pharmaceutical pursuit has been more cautious than the pathway's mechanistic appeal would suggest.
Community discussion notes
Less discussed in biohacker communities than incretin candidates, partly because the human-development pathway is earlier-stage. Of considerable academic and pharmaceutical interest as a distinct molecular target for appetite regulation.
The takeaway
GDF15 mimetics represent a credible third or fourth therapeutic axis for obesity beyond the incretin and amylin classes. Whether the nausea-vs-appetite-suppression therapeutic window can be engineered favorably is the central question for the class as a whole.
References
- Borner T, et al. GDF15 induces anorexia through nausea and emesis. Cell Metab. 2020;31(2):351-362. https://pubmed.ncbi.nlm.nih.gov/31928886/
- Mullican SE, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med. 2017;23(10):1150-1157. https://pubmed.ncbi.nlm.nih.gov/28846098/